|
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A molecular variant of angiotensinogen is associated with diabetic nephropathy in IDDM.
|
8772723 |
1996 |
|
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Conflicting results on the relationship between M235T polymorphism of angiotensinogen (AGT) gene and diabetic nephropathy are reported in the literature, probably due to the small number of subjects, to different inclusion criteria and the different genotype analysis methods used.
|
12270765 |
2002 |
|
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These data suggest that the augmented angiotensinogen mRNA levels in segment 3 and angiotensinogen protein levels in segments 1 and 3 may contribute to the progression of diabetic nephropathy.
|
24910532 |
2014 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although key signal transduction and gene regulation mechanisms have been identified, especially those related to the effects of hyperglycaemia, transforming growth factor β1 and angiotensin II, progress in functional genomics, high-throughput sequencing technology, epigenetics and systems biology approaches have greatly expanded our knowledge and uncovered new molecular mechanisms and factors involved in DN.
|
25003613 |
2014 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Angiotensin converting enzyme (ACE) generates angiotensin II from angiotensin I, which plays a critical role in the pathophysiology of diabetic nephropathy.
|
19034303 |
2008 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
A key driving factor of diabetic nephropathy is angiotensin II acting via the G-protein-coupled cell membrane type 1 receptor.
|
30190172 |
2018 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Angiotensin converting enzyme 2 (ACE2) is highly expressed in the kidney and recognized to be renoprotective by degrading Angiotensin II to Angiotensin (1-7) in diabetic nephropathy.
|
25791940 |
2015 |
|
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
ACE and AGT gene polymorphisms may not play a role in the protective or accelerative effect against the development of diabetic nephropathy in the patients with or without proliferative retinopathy, but ACE gene polymorphism might be related to an arteriosclerotic family history in Japanese IDDM patients.
|
10499884 |
1999 |
|
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Therefore, we investigated the long-term effect of the angiotensin II subtype-1 (AT1) receptor antagonist losartan (100 mg o.d.) on kidney function in II and DD type 1 diabetic patients with diabetic nephropathy.
|
12716812 |
2003 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
In fact, it has been shown that angiotensin II is involved in almost every pathophysiological process implicated in the development of diabetic nephropathy (haemodynamic changes, hypertrophy, extracellular matrix accumulation, growth factor/cytokine induction, ROS formation, podocyte damage, proteinuria, interstitial inflammation).
|
15606719 |
2004 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Angiotensin II, reactive oxygen species, and other factors in the setting of DKD stimulate drastic increases in calcium influx through the TRPC6 channel, causing podocyte hypertrophy and foot process effacement.
|
31115705 |
2019 |
|
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Microvascular complications were graded as follows: neuropathy by clinical assessment, electrophysiology, vibration and cooling detection thresholds, heart rate variability, and corneal confocal microscopy; retinopathy by ultra-wide-field retinal imaging; and DKD by renal hemodynamic function measured by inulin and para-aminohippurate clearance at baseline and after intravenous infusion of angiotensin II.
|
30275283 |
2018 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Angiotensin-converting enzyme 2: enhancing the degradation of angiotensin II as a potential therapy for diabetic nephropathy.
|
22113528 |
2012 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The intrarenal renin-angiotensin system, in particular augmentation of angiotensinogen (AGT) in proximal tubular cells (PTC), plays a crucial role in the development of diabetic nephropathy.
|
30466736 |
2019 |
|
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Podocytes have also been shown to express angiotensin-converting enzyme 2 (ACE2), which can decrease angiotensin II levels by generation of angiotensin-(1-7).Nadarajah et al. now show that increased podocyte ACE2 activity can attenuate the development of diabetic nephropathy.
|
22791320 |
2012 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The two main treatment strategies for prevention of diabetic nephropathy are improved glycaemic control and blood pressure lowering, particularly using drugs such angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists.
|
12682618 |
2003 |
|
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Comprehensive electronic search in Pubmed, Web of Science, EBSCO, Embase, the Cochrane Library and China National Knowledge Infrastructure (CNKI) to find original articles about the association between AGT M235T polymorphism and DN risk published before 27 September 2017.
|
29775675 |
2018 |
|
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study is a continuation of our previous research on the association between angiotensinogen (AGT) gene polymorphisms and DN in patients with T2DM.
|
29514038 |
2018 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Further, we discovered that the genes encoding the angiotensin-converting enzyme, angiotensinogen, and angiotensin II type I receptor have a significant combinational effect on conferring susceptibility to diabetic nephropathy.
|
17653210 |
2007 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
In an attempt to overcome this interaction, we evaluated the short-term renoprotective effect in diabetic nephropathy of the angiotensin II receptor antagonist losartan in patients homozygous for the insertion or the deletion allele.
|
12081578 |
2002 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Angiotensinogen was selected because of the putative link between it and mild to moderate essential hypertension and nephrosclerosis; angiotensin-converting enzyme because of its possible contribution to diabetic nephropathy; and renin, the angiotensin II receptor, and kallikrein because of their roles in hypertension and renal perfusion.
|
8989734 |
1996 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
It is noteworthy that the efferent glomerular arteriole is 10 - 100 times more sensitive to the vasoconstrictive properties of angiotensin II than the afferent one and this might account for the consequently higher intra-glomerular capillary pressure, which is believed to be the cornerstone of diabetic nephropathy.
|
28177279 |
2017 |
|
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
DN (+) DUR < 5 years group had greatly increased frequencies of AGT-M235T allele and ACE-DD genotype in comparison with DN(-) group (0.92 vs 0.68 and 0.28 vs 0.05, respectively).
|
11776100 |
2000 |
|
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The regions containing ACE and AGT loci were not linked with DN, while the region containing the AT1 locus showed linkage with DN.
|
9648845 |
1998 |
|
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
High glucose and angiotensin-II (Ang-II) levels are the known important mediators of diabetic nephropathy.
|
16728425 |
2006 |